All data are based on the daily closing price as of December 24, 2024
l
Lumosa Therapeutics
6535.TWO
6.16 USD
-0.01
-0.16%
Overview
Last close
6.16 usd
Market cap
1.02B usd
52 week high
12.06 usd
52 week low
1.81 usd
Target price
7.26 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
713.2803
Price/Book Value
28.7486
Enterprise Value
998.23M usd
EV/Revenue
863.2056
EV/EBITDA
N/A
Key financials
Revenue TTM
1.46M usd
Gross Profit TTM
N/A usd
EBITDA TTM
-10.25M usd
Earnings per Share
-0.07 usd
Dividend
N/A usd
Total assets
1.60B usd
Net debt
-279.44M usd
About
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.